Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534195 | 0.84 | PARP1 (0.62) | PARP1HPGDKDM4EALDH1A1 | |
| SCHEMBL5520231 | 0.82 | PARP1 (0.61) | PARP1KDM4EALDH1A1 | |
| SCHEMBL5526545 | 0.78 | PARP1 (0.59) | PARP1KDM4E | |
| SCHEMBL5520379 | 0.77 | PARP1 (0.56) | PARP1 | |
| SCHEMBL5522637 | 0.76 | PARP1 (0.62) | PARP1 | |
| SCHEMBL5525103 | 0.74 | PARP1 (0.67) | PARP1HPGDKDM4EALDH1A1 | |
| SCHEMBL4761629 | 0.72 | PARP1 (1.00) | PARP1HPGDKDM4EALDH1A1 | |
| SCHEMBL5526110 | 0.71 | PARP1 (0.55) | PARP1 | |
| SCHEMBL5534213 | 0.71 | PARP1 (0.55) | PARP1 | |
| SCHEMBL5526070 | 0.71 | PARP1 (0.55) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-10-25 | — | — | US | claimed |
| EP-2468748-B1 | Pyrazoloquinolones are potent parp inhibitors | ABBVIE INC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-1989204-B1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8546368-B2 | Pyrazoloquinolones are potent PARP inhibitors | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2468748-A1 | Pyrazoloquinolones are potent parp inhibitors | Abbott Laboratories (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885HPGD 120/4885KDM4E 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.